Bio-R
Bio-Rad Laboratories (BIO) got here out with quarterly earnings of $2.32 per share, lacking the Zacks Consensus Estimate of $2.46 per share. This compares to earnings of $2.13 per share a yr in the past. These figures are adjusted for non-recurring objects.
This quarterly report represents an earnings shock of -5.69%. 1 / 4 in the past, it was anticipated that this maker of devices utilized in biomedical analysis would publish earnings of $1.36 per share when it truly produced earnings of $1.61, delivering a shock of 18.38%.
Over the past 4 quarters, the corporate has surpassed consensus EPS estimates thrice.
Bio-Rad, which belongs to the Zacks Medical – Merchandise business, posted revenues of $624.43 million for the quarter ended December 2019, lacking the Zacks Consensus Estimate by 1.90%. This compares to year-ago revenues of $617.54 million. The corporate has topped consensus income estimates two instances during the last 4 quarters.
…